Sino Biopharmaceutical Presents Lung Cancer Drug Trial Data at US Oncology Society Meeting

MT Newswires Live

May 23, 2025

Sino Biopharmaceutical (HKG:1177) presented the latest results of a Benmelstobart injection study to treat advanced squamous non-small cell lung cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, a Friday Hong Kong bourse filing said.

The phase III clinical trial studies the use of the drug in combination with chemotherapy, followed by sequential combination with Anlotinib Hydrochloride capsules, versus the Tislelizumab injection in combination with chemotherapy.

The trial shows that the drug in combination with the other therapies significantly prolonged median progression-free survival compared with Tislelizumab, reducing the risk of disease progression or death by 36% in the trial group.

The overall safety of the trial group was also good.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2537135011"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537135011\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537135011?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-23 19:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537135011","market":"us","top_or_hot":-1,"title":"Sino Biopharmaceutical Presents Lung Cancer Drug Trial Data at US Oncology Society Meeting","media":"MT Newswires Live","content":"<html><body><p> Sino Biopharmaceutical (HKG:1177) presented the latest results of a Benmelstobart injection study to treat advanced squamous non-small cell lung cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, a Friday Hong Kong bourse filing said.</p><p>The phase III clinical trial studies the use of the drug in combination with chemotherapy, followed by sequential combination with Anlotinib Hydrochloride capsules, versus the Tislelizumab injection in combination with chemotherapy.</p><p>The trial shows that the drug in combination with the other therapies significantly prolonged median progression-free survival compared with Tislelizumab, reducing the risk of disease progression or death by 36% in the trial group.</p><p>The overall safety of the trial group was also good.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharmaceutical Presents Lung Cancer Drug Trial Data at US Oncology Society Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharmaceutical Presents Lung Cancer Drug Trial Data at US Oncology Society Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-23 19:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Sino Biopharmaceutical (HKG:1177) presented the latest results of a Benmelstobart injection study to treat advanced squamous non-small cell lung cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, a Friday Hong Kong bourse filing said.</p><p>The phase III clinical trial studies the use of the drug in combination with chemotherapy, followed by sequential combination with Anlotinib Hydrochloride capsules, versus the Tislelizumab injection in combination with chemotherapy.</p><p>The trial shows that the drug in combination with the other therapies significantly prolonged median progression-free survival compared with Tislelizumab, reducing the risk of disease progression or death by 36% in the trial group.</p><p>The overall safety of the trial group was also good.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2537135011","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537135011","pubTimestamp":1748001055,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sino Biopharmaceutical  presented the latest results of a Benmelstobart injection study to treat advanced squamous non-small cell lung cancer at the 2025 American Society of Clinical Oncology  Annual Meeting, a Friday Hong Kong bourse filing said.The phase III clinical trial studies the use of the drug in combination with chemotherapy, followed by sequential combination with Anlotinib Hydrochloride capsules, versus the Tislelizumab injection in combination with chemotherapy.The trial shows that the drug in combination with the other therapies significantly prolonged median progression-free survival compared with Tislelizumab, reducing the risk of disease progression or death by 36% in the trial group.The overall safety of the trial group was also good.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓","01177":"中国生物制药","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1589":"北水核心资产"},"translate_title":"中国生物制药在美国肿瘤学会会议上展示肺癌药物试验数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":0.9},"content_text":"Sino Biopharmaceutical (HKG:1177) presented the latest results of a Benmelstobart injection study to treat advanced squamous non-small cell lung cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, a Friday Hong Kong bourse filing said.The phase III clinical trial studies the use of the drug in combination with chemotherapy, followed by sequential combination with Anlotinib Hydrochloride capsules, versus the Tislelizumab injection in combination with chemotherapy.The trial shows that the drug in combination with the other therapies significantly prolonged median progression-free survival compared with Tislelizumab, reducing the risk of disease progression or death by 36% in the trial group.The overall safety of the trial group was also good.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}